Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests.
The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after treatment, particularly African American men who face the highest burden from this disease.
This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative stress, apoptosis, and angiogenesis through multiple cancer-related signaling pathways. While biologically plausible, the findings are largely limited to cell and animal models, underscoring the need for pharmacokinetic, safety, and clinical validation.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
